Abstract: Polyesters according to the following formula (I) are described wherein R1 and R2 independently of one another are X—(OC2H4)n—(OC3H6)m wherein X is C1-4 alkyl, the —(OC2H4) groups and the —(OC3H6) groups are arranged blockwise and the block consisting of the —(OC3H6) groups is bound to a COO group or are HO—(C3H6), n is based on a molar average a number of from 12 to 120, m is based on a molar average a number of from 1 to 10, and a is based on a molar average a number of from 4 to 9. The inventive polyesters have an advantageous stability in alkaline environment, possess a beneficial solubility and advantageously are clearly soluble in alkaline compositions such as alkaline heavy duty washing liquids and also possess advantageous soil release properties.

Abstract: Chemical agents, such as disulfonamide derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine, and similar heterocyclic ring structures; including, salts thereof that act as anti-cancer and anti-tumor agents, along with methods for preparing such agents, as well as pharmaceutical compositions containing such agents as active ingredients and methods of using these as therapeutic agents.

Abstract: Disclosed is a method of reducing the ultraviolet-light absorbing properties of a composition comprising dioctyl phthalate, the method comprising (a) obtaining a composition comprising dioctyl phthalate and phthalide, wherein said composition has an absorbance of greater than 0.1 at a wavelength of about from 230 to 360 nm, (b) contacting the composition with activated carbon, silica gel, or diatomaceous earth, for a sufficient amount of time to allow the phthalide to contact the activated carbon, silica gel, or diatomaceous earth, and (c) removing the composition from the activated carbon, silica gel, or diatomaceous earth, wherein the composition obtained from step (c) has an absorbance equal to or less than about 0.1 at a wavelength of about from 230 to 360 nm and has a reduced amount of phthalide when compared with the composition from step (a).

Abstract: A process of converting a carbon-carbon multiple bond to a cyclopropane ring, comprising the addition of a N-alkyl-N-nitroso compound to a mixture of alkene precursor, aqueous base and Pd(II)-catalyst, with the N-alkyl-N-nitroso compound obtained directly from an alkyl amine derivative, NaNO2 and an acid via phase separation of the N-alkyl-N-nitroso compound from the aqueous phase.

Abstract: Sulfonate-, sulfate-, or carboxylate-capped, alkoxylated anti-misting agents having the structure: R((AO)nX)m((AO)nH)p, and methods of suppressing mist from electrolyte solutions by adding a mist-suppressing amount of one or more compounds selected from the group consisting of compounds of the Formulas R((AO)nX)m((AO)nH)p and R3N+(CH3)2R4, and mixtures thereof, to electrolyte solutions.

Abstract: The disclosure provides compounds of formula I including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic 7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.

Abstract: A method of killing bacteria. The method includes contacting the bacteria with an effective amount of at least one oxidation product of safranal selected from the group consisting of a compound of formula II, a compound of formula III, and stereoisomers thereof. The oxidation products of safranal of formula II and/or formula III are preferably synthesized by subjecting safranal to oxidation reactions either photochemically with at least one peroxide in the presence of light or thermally with at least one organic peracid.

Abstract: Poly alkanolamines formed as the reaction products of secondary or tertiary alkanolamines, C8-C24 fatty acids, and shorter chain organic acids are provided, which serve as excellent petroleum/water emulsion breakers for water-in-oil emulsions and reverse oil-in-water emulsions. The polymers are preferably prepared using a reaction mixture of triethanolamine, tall oil fatty acids, and acetic acid.

Abstract: A method for continuously preparing biuret polyisocyanate, comprising: a mixed solution of a diisocyanate and a catalyst with water vapour, in an aerosol form, are continuously reacted in a first reactor; the product obtained therefrom is brought into a second reactor for a further reaction; a tail gas from the second reactor is condensed and refluxed, and the non-condensable gas is brought into a tail gas treatment system; a reaction liquid obtained in the second reactor is further reacted in a third reactor; and then separation is performed for removing monomers, so as to obtain biuret polyisocyanate.

Abstract: The present disclosure provides compounds that include a tetrazolone derivative of a carboxyl group of an active agent. This disclosure also relates to pharmaceutical compositions that include these compounds, methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.

Abstract: Anti-angiogenic treatments, treatments of hyperpermeability disorders, treatments of neuropathic and neurodegenerative disorders, pain treatments, methods of reducing the risk of pre-eclampsia and compounds for use in such methods are described.

Abstract: A process for producing acetic acid comprising the steps of carbonylating methanol in a reaction medium to form a crude acetic acid product; conveying the crude acetic acid product to a flash vessel at a flash flow rate; flashing the crude acetic acid product to form a first vapor stream comprising acetic acid and a liquid residue stream comprising metal catalyst and halide salt; separating the flashed vapor stream to form a second vapor stream comprising methyl iodide a sidedraw comprising purified acetic acid and water, and a liquid residue stream. The process further comprises the steps of condensing at least a portion of the second vapor stream to form at least one liquid phase and refluxing to the light ends column at least a portion of the at least one liquid phase at a reflux rate. The reflux rate is adjusted based on changes in the flash flow rate.

Abstract: Contained herein are compositions, formulations, methods, and kits for treating regional fat deposits and fat-related conditions. Certain methods comprise administering tetradecyl sulfate, tetradecyl sulfate-like compounds, and pharmaceutically or cosmetically acceptable salts, solvates, prodrugs, or esters thereof and a liquid carrier.

Abstract: Provided herein are methods that utilize polyhydroxyalkanoates (PHAs) as a substrate for further conversion to C4 and C5 compounds. Polyhydroxyalkanoates can undergo esterification to yield alkyl hydroxyalkanoates and alkyl alkenoates, which may serve as useful precursors in the production of alkadienes and alkenedioic acids, including for example butadiene and butenedioic acid.

Abstract: The invention relates to terpene-derived acids and esters thereof as well as to processes for synthesizing them.

Abstract: The present invention relates to compositions and methods for the treatment of infection by enveloped viruses, such as Ebola and Lassa fever viruses.

Abstract: A method of making a benzyl cis-cyclohexane 1,2-dicarboxylate triester having the steps: a. forming a reaction mixture by reacting the following three components: i. a synthetic or biobased reagent selected from the group consisting of an alpha-hydroxyester and a beta-hydroxyester, ii. an anhydride selected from the group consisting of cis-hexahydrophthalic anhydride, 4-methylcyclohexane-1,2-dicarboxylic anhydride, and 3-methylcyclohexane-1,2-dicarboxylic anhydride, and iii. an alkylamine catalyst; and b. contacting benzyl chloride with the reaction mixture to yield a product that is free of phthalates and includes at least one benzyl cis-cyclohexane 1,2-dicarboxylate triester.

Abstract: The present invention provides crystalline forms of a compound of formula (I): Also provided are pharmaceutical compositions that include the provided crystalline forms and methods of using the provided crystalline forms and pharmaceutical compositions for the treatment of cancer.

Abstract: Disclosed are a sulfonylindole derivative useful for the prevention or treatment of peptic ulcer, gastritis or reflux esophagitis, a method of preparing the same, and a pharmaceutical composition containing the same.

Abstract: The present invention provides methods for treating seizure disorders. The method includes administering to a subject in need thereof 2-amino-6-trifluoromethylthio-benzothiazole, or a pharmaceutically acceptable salt thereof. Methods for the treatment of pain are also described.